Recent advances in the medical therapy of Crohn's disease in childhood

Bibliography

• BREMNER AR, BEATTIE RM: Therapy of Crohn's disease in childhood. Expert Opin. Pharmacother. (2002) 3:809-825.
   PubMedGoogle Scholar
• BEATTIE RM, CROFT NM, FELL JM, AFZAL NA, HEUSCHKEL RB: Inflammatory bowel disease. Arch. Dis. Child. (2006) 91:426-432.
   PubMed Web of Science ®Google Scholar
• IBD WORKING GROUP OF ESPGHAN: Inflammatory bowel disease in children and adolescents: recommendations for diagnosis – the Porto criteria. J. Pediatr. Gastroenterol. Nutr. (2005) 41:1-7.
   PubMed Web of Science ®Google Scholar
• SAWCZENKO A, BALLINGER AB, SAVAGE MO, SANDERSON IR: Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics (2006) 118:124-129.
   PubMed Web of Science ®Google Scholar
• ALEMZADEH N, REKERS-MOMBARG LT, MEARIN ML et al.: Adult height in patients with early onset of Crohn's disease. Gut (2002) 51:26-29.
   PubMedGoogle Scholar
• CAPRILLI R, GASSULL MA, ESCHER JC et al.: European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 55(Suppl. 1):I36-I58.
   PubMed Web of Science ®Google Scholar
• TRAVIS SP, STANGE EF, LEMANN M et al.: European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 55(Suppl. 1):I16-I35.
   PubMed Web of Science ®Google Scholar
• STANGE EF, TRAVIS SP, VERMEIRE S et al.: European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 55(Suppl. 1):I1-I15.
   Google Scholar
• KONNO M, KOBAYASHI A, TOMOMASA T et al.: Guidelines for the treatment of Crohn's disease in children. Pediatr. Int. (2006) 48:349-352.
   PubMedGoogle Scholar
• HEUSCHKEL RB, MENACHE CC, MEGERIAN JT, BAIRD AE: Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. (2000) 31:8-15.
   PubMed Web of Science ®Google Scholar
• DAY AS, WHITTEN KE, LEMBERG DA et al.: Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J. Gastroenterol. Hepatol. (2006) 21:1609-1614.
   PubMed Web of Science ®Google Scholar
• BORRELLI O, CORDISCHI L, CIRULLI M et al.: Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. (2006) 4:744-753.
   PubMed Web of Science ®Google Scholar
• AFZAL NA, DAVIES S, PAINTIN M et al.: Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci. (2005) 50:1471-1475.
   PubMedGoogle Scholar
• GAVIN J, ANDERSON CE, BREMNER AR, BEATTIE RM: Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J. Hum. Nutr. Diet. (2005) 18:337-342.
   PubMedGoogle Scholar
• HART JW, BREMNER AR, WOOTTON SA, BEATTIE RM: Measured versus predicted energy expenditure in children with inactive Crohn's disease. Clin. Nutr. (2005) 24:1047-1055.
   PubMedGoogle Scholar
• JOHNSON T, MACDONALD S, HILL SM, THOMAS A, MURPHY MS: Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut (2006) 55:356-361.
   PubMed Web of Science ®Google Scholar
• VERMA S, HOLDSWORTH CD, GIAFFER MH: Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand. J. Gastroenterol. (2001) 36:383-388.
   PubMed Web of Science ®Google Scholar
• TAKAGI S, UTSUNOMIYA K, KURIYAMA S et al.: Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment. Pharmacol. Ther. (2006) 24:1333-1340.
   PubMed Web of Science ®Google Scholar
• STEINHART AH, EWE K, GRIFFITHS AM, MODIGLIANI R, THOMSEN OO: Corticosteroids for maintaining remission of Crohn's disease (Cochrane Review). Cochrane Database Syst. Rev. (2001) 3:CD000301.
   Google Scholar
• SIMMS LSTEINHART AH: Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. (2001):CD002913.
   Google Scholar
• DILGER K, ALBERER M, BUSCH A et al.: Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment. Pharmacol. Ther. (2006) 23:387-396.
   PubMed Web of Science ®Google Scholar
• OTLEY A, STEINHART AH: Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. (2005):CD000296.
   Google Scholar
• ESCHER JC: Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur. J. Gastroenterol. Hepatol. (2004) 16:47-54.
   PubMed Web of Science ®Google Scholar
• TUNG J, LOFTUS EV Jr, FREESE DK et al.: A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. (2006) 12:1093-1100.
   PubMed Web of Science ®Google Scholar
• BERGMAN R, PARKES M: Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. (2006) 23:841-855.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, STROMBERG U: Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin. Gastroenterol. Hepatol. (2004) 2:379-388.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZZELLO F, LAMMERS KM et al.: Antimicrobials in the management of inflammatory bowel disease. Digestion (2006) 73(Suppl. 1):77-85.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, VAN ASSCHE G, VERMEIRE S et al.: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2005) 128:856-861.
   PubMed Web of Science ®Google Scholar
• JASPERS GJ, VERKADE HJ, ESCHER JC et al.: Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm. Bowel Dis. (2006) 12:831-836.
   PubMedGoogle Scholar
• MARKOWITZ J, GRANCHER K, KOHN N, LESSER M, DAUM F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease (see comments). Gastroenterology (2000) 119:895-902.
   PubMed Web of Science ®Google Scholar
• HOLTMANN MH, KRUMMENAUER F, CLAAS C et al.: Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig. Dis. Sci. (2006) 51:1516-1524.
   PubMed Web of Science ®Google Scholar
• SCHEDEL J, GODDE A, SCHUTZ E et al.: Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Ann. NY Acad. Sci. (2006) 1069:477-491.
   PubMed Web of Science ®Google Scholar
• HINDORF U, LINDQVIST M, PETERSON C et al.: Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut (2006) 55:1423-1431.
   PubMed Web of Science ®Google Scholar
• HANDE S, WILSON-RICH N, BOUSVAROS A et al.: 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm. Bowel Dis. (2006) 12:251-257.
   PubMed Web of Science ®Google Scholar
• DOMENECH E, NOS P, PAPO M et al.: 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand. J. Gastroenterol. (2005) 40:52-55.
   PubMed Web of Science ®Google Scholar
• KANDIEL A, FRASER AG, KORELITZ BI, BRENSINGER C, LEWIS JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 54:1121-1125.
   PubMed Web of Science ®Google Scholar
• MACK DR, YOUNG R, KAUFMAN SS, RAMEY L, VANDERHOOF JA: Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J. Pediatr. (1998) 132:830-835.
   PubMed Web of Science ®Google Scholar
• UHLEN S, BELBOUAB R, NAREBSKI K et al.: Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm. Bowel Dis. (2006) 12:1053-1057.
   PubMed Web of Science ®Google Scholar
• ALFADHLI AA, MCDONALD JW, FEAGAN BG: Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. (2005):CD003459.
   Google Scholar
• CARTER MJ, LOBO AJ, TRAVIS SP: Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 53(Suppl. 5):V1-V16.
   PubMed Web of Science ®Google Scholar
• STEPHENS MC, BALDASSANO RN, YORK A et al.: The bioavailability of oral methotrexate in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2005) 40:445-449.
   PubMed Web of Science ®Google Scholar
• MCDONALD JW, FEAGAN BG, JEWELL D et al.: Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. (2005):CD000297.
   Google Scholar
• BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. J. Pediatr. (2000) 137:794-799.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-LAMA Y, ABREU L, VERA MI et al.: Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. (2005) 11:8-15.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-LAMA Y, GISBERT JP, MATE J: The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig. Dis. Sci. (2006).
   PubMedGoogle Scholar
• BAUMGART DC, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17:1273-1281.
   PubMed Web of Science ®Google Scholar
• CHANG RK, MCDIARMID SV, ALEJOS JC, DRANT SE, KLITZNER TS: Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation. Pediatr. Transplant. (2001) 5:187-191.
   PubMedGoogle Scholar
• SHAPIRO R, SCANTLEBURY VP, JORDAN ML et al.: Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation (1999) 67:299-303.
   PubMedGoogle Scholar
• WENZL HH, HINTERLEITNER TA, AICHBICHLER BW, FICKERT P, PETRITSCH W: Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. Aliment. Pharmacol. Ther. (2004) 19:427-434.
   PubMed Web of Science ®Google Scholar
• SKELLY MM, LOGAN RF, JENKINS D, MAHIDA YR, HAWKEY CJ: Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm. Bowel Dis. (2002) 8:93-97.
   PubMed Web of Science ®Google Scholar
• STALLMACH A, WITTIG BM, MOSER C et al.: Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut (2003) 52:377-382.
   PubMed Web of Science ®Google Scholar
• SCHMIDT C, WITTIG BM, MOSER C, ZEITZ M, STALLMACH A: Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. Aliment. Pharmacol. Ther. (2006) 24:343-350.
   PubMedGoogle Scholar
• MURCH SH, BRAEGGER CP, WALKER-SMITH JA, MACDONALD TT: Location of TNF-α by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 34:1705-1709.
   PubMed Web of Science ®Google Scholar
• BREESE EJ, MICHIE CA, NICHOLLS SW et al.: TNF-α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology (1994) 106:1455-1466.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to TNF-α for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. (1997) 337:1029-1035.
   PubMed Web of Science ®Google Scholar
• AKOBENG AK, ZACHOS M: TNF-α antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. (2004):CD003574.
   Google Scholar
• HYAMS JS, MARKOWITZ J, WYLLIE R: Use of infliximab in the treatment of Crohn's disease in children and adolescents. J. Pediatr. (2000) 137:192-196.
   PubMed Web of Science ®Google Scholar
• SERRANO MS, SCHMIDT-SOMMERFELD E, KILBAUGH TJ et al.: Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. (2001) 35:823-828.
   PubMed Web of Science ®Google Scholar
• BALDASSANO R, BRAEGGER CP, ESCHER JC et al.: Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. (2003) 98:833-838.
   PubMed Web of Science ®Google Scholar
• LAMIREAU T, CEZARD JP, DABADIE A et al.: Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm. Bowel Dis. (2004) 10:745-750.
   PubMed Web of Science ®Google Scholar
• STEPHENS MC, SHEPANSKI MA, MAMULA P et al.: Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am. J. Gastroenterol. (2003) 98:104-111.
   PubMed Web of Science ®Google Scholar
• LEMANN M, MARY JY, DUCLOS B et al.: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 130:1054-1061.
   PubMed Web of Science ®Google Scholar
• SCHRODER O, BLUMENSTEIN I, STEIN J: Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur. J. Gastroenterol. Hepatol. (2006) 18:11-16.
   PubMedGoogle Scholar
• LIONETTI P, BRONZINI F, SALVESTRINI C et al.: Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment. Pharmacol. Ther. (2003) 18:425-431.
   PubMed Web of Science ®Google Scholar
• KUGATHASAN S, WERLIN SL, MARTINEZ A et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. J. Gastroenterol. (2000) 95:3189-3194.
   PubMed Web of Science ®Google Scholar
• CEZARD JP, NOUAILI N, TALBOTEC C et al.: A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2003) 36:632-636.
   PubMed Web of Science ®Google Scholar
• WEWER V, RIIS L, VIND I et al.: Infliximab dependency in a national cohort of children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. (2006) 42:40-45.
   PubMed Web of Science ®Google Scholar
• HYAMS J, CRANDALL W, KUGATHASAN S, GRIFFITHS A: Maintenance therapy with infliximab every 8 weeks is superior to every 12 weeks in maintaining response and remission in pediatric patients with moderately to severely active Crohn's disease. Gastroenterology (2006) 130.
   PubMedGoogle Scholar
• SANDS BE, BLANK MA, DIAMOND RH, BARRETT JP, VAN DEVENTER SJ: Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment. Pharmacol. Ther. (2006) 23:1127-1136.
   PubMed Web of Science ®Google Scholar
• FREEMAN HJ, FLAK B: Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can. J. Gastroenterol. (2005) 19:313-316.
   PubMed Web of Science ®Google Scholar
• THOMAS CW Jr, WEINSHENKER BG, SANDBORN WJ: Demyelination during anti-TNF-α therapy with infliximab for Crohn's disease. Inflamm. Bowel Dis. (2004) 10:28-31.
   PubMed Web of Science ®Google Scholar
• LJUNG T, KARLEN P, SCHMIDT D et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 53:849-853.
   PubMed Web of Science ®Google Scholar
• BIANCONE L, ORLANDO A, KOHN A et al.: Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2006) 55:228-233.
   PubMed Web of Science ®Google Scholar
• SIEGEL CA, HUR C, KORZENIK JR, GAZELLE GS, SANDS BE: Risks and benefits of infliximab for the treatment of Crohn's disease. Clin. Gastroenterol. Hepatol. (2006) 4:1017-1024.
   PubMed Web of Science ®Google Scholar
• BUCHER C, DEGEN L, DIRNHOFER S et al.: Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut (2005) 54:732-733.
   PubMedGoogle Scholar
• LOSCO A, GIANELLI U, CASSANI B et al.: Epstein–Barr virus-associated lymphoma in Crohn's disease. Inflamm. Bowel Dis. (2004) 10:425-429.
   PubMed Web of Science ®Google Scholar
• THAYU M, MARKOWITZ JE, MAMULA P et al.: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2005) 40:220-222.
   PubMed Web of Science ®Google Scholar
• MACKEY AC, GREEN L, LIANG LC, DINNDORF P, AVIGAN M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2007) 44:265-267.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ J, HYAMS J, MACK D et al.: Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin. Gastroenterol. Hepatol. (2006) 4:1124-1129.
   PubMed Web of Science ®Google Scholar
• DE RIDDER L, BENNINGA MA, TAMINIAU JA, HOMMES DW: Infliximab as first-line therapy in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2006) 43:388-390.
   PubMedGoogle Scholar
• CANDON S, MOSCA A, RUEMMELE F et al.: Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin. Immunol. (2006) 118:11-19.
   PubMed Web of Science ®Google Scholar
• STACK WA, MANN SD, ROY AJ et al.: Randomised controlled trial of CDP571 antibody to TNF-α in Crohn's disease. Lancet (1997) 349:521-524.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FEAGAN BG, RADFORD-SMITH G et al.: CDP571, a humanised monoclonal antibody to TNF-α, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut (2004) 53:1485-1493.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, SANDBORN WJ, BAKER JP et al.: A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with corticosteroid-dependent Crohn's disease. Aliment. Pharmacol. Ther. (2005) 21:373-384.
   PubMed Web of Science ®Google Scholar
• MAMULA P, COHEN SA, FERRY GD et al.: CDP571, a humanized anti-TNF-α monoclonal antibody in pediatric Crohn's disease. Inflamm. Bowel Dis. (2004) 10:723-730.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, SANDBORN WJ, RUTGEERTS P et al.: Human anti-TNF monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 130:323-333.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, SANDBORN WJ, RUTGEERTS P et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2007) 132:52-65.
   PubMed Web of Science ®Google Scholar
• MIAN S, BARON H: Adalimumab, a novel anti-TNF-antibody in a child with refractory Crohn's disease. J. Pediatr. Gastroenterol. Nutr. (2005) 41:357-359.
   PubMedGoogle Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088-1094.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, SANDBORN WJ, FEDORAK RN et al.: Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2006) 4:888-893.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, RUTGEERTS P, FEDORAK RN et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 129:807-818.
   PubMed Web of Science ®Google Scholar
• BAUDITZ J, WEDEL S, LOCHS H: Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 50:196-200.
   PubMed Web of Science ®Google Scholar
• FACCHINI S, CANDUSSO M, MARTELOSSI S et al.: Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J. Pediatr. Gastroenterol. Nutr. (2001) 32:178-181.
   PubMed Web of Science ®Google Scholar
• SABATE JM, VILLAREJO J, LEMANN M et al.: An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther. (2002) 16:1117-1124.
   PubMed Web of Science ®Google Scholar
• KANE S, STONE LJ, EHRENPREIS E: Thalidomide as “salvage” therapy for patients with delayed hypersensitivity response to infliximab: a case series. J. Clin. Gastroenterol. (2002) 35:149-150.
   PubMed Web of Science ®Google Scholar
• MACDONALD JK, MCDONALD JW: Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. (2006) 3:CD006097.
   Google Scholar
• SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. (2005) 353:1912-1925.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, GREENBERG G, WILD G: Efficacy and safety of a humanized α4 β4 antibody in active Crohn's disease. Gastroenterology (2006) 124:A25-A26.
   Google Scholar
• YACYSHYN BR, CHEY WY, GOFF J et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut (2002) 51:30-36.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, BARISH C, GOFF J et al.: Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment. Pharmacol. Ther. (2002) 16:1761-1770.
   PubMed Web of Science ®Google Scholar
• ITO H, TAKAZOE M, FUKUDA Y et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 126:989-996.
   PubMed Web of Science ®Google Scholar
• WATFORD WT, MORIGUCHI M, MORINOBU A, O'SHEA JJ: The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. (2003) 14:361-368.
   Google Scholar
• MANNON PJ, FUSS IJ, MAYER L et al.: Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. (2004) 351:2069-2079.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, FEAGAN B, D'HAENS G et al.: Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2006) 4:325-334.
   PubMed Web of Science ®Google Scholar
• SANDS BE, WINSTON BD, SALZBERG B et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment. Pharmacol. Ther. (2002) 16:399-406.
   PubMed Web of Science ®Google Scholar
• HERRLINGER KR, WITTHOEFT T, RAEDLER A et al.: Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am. J. Gastroenterol. (2006) 101:793-797.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, DIECKGRAEFE BK, VALENTINE JF, HAUSMAN DF, GILBERT MJ: Sargramostim for active Crohn's disease. N. Engl. J. Med. (2005) 352:2193-2201.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, DIECKGRAEFE BK: An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment. Pharmacol. Ther. (2005) 21:391-400.
   PubMedGoogle Scholar
• CONTE MP, SCHIPPA S, ZAMBONI I et al.: Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut (2006) 55:1760-1767.
   PubMed Web of Science ®Google Scholar
• ROLFE VE, FORTUN PJ, HAWKEY CJ, BATH-HEXTALL F: Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. (2006): CD004826.
   Google Scholar
• BOUSVAROS A, GUANDALINI S, BALDASSANO RN et al.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. (2005) 11:833-839.
   PubMed Web of Science ®Google Scholar
• MARTEAU P, LEMANN M, SEKSIK P et al.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut (2006) 55:842-847.
   PubMed Web of Science ®Google Scholar
• LINDSAY JO, WHELAN K, STAGG AJ et al.: Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut (2006) 55:348-355.
   PubMed Web of Science ®Google Scholar
• SEGAIN JP, RAINGEARD DE LA BD, BOURREILLE A et al.: Butyrate inhibits inflammatory responses through NF-κβ inhibition: implications for Crohn's disease. Gut (2000) 47:397-403.
   PubMed Web of Science ®Google Scholar
• KLAMPFER L, HUANG J, SASAZUKI T, SHIRASAWA S, AUGENLICHT L: Inhibition of interferon γ signaling by the short chain fatty acid butyrate. Mol. Cancer Res. (2003) 1:855-862.
   PubMed Web of Science ®Google Scholar
• DI SABATINO A, MORERA R, CICCOCIOPPO R et al.: Oral butyrate for mildly to moderately active Crohn's disease. Aliment. Pharmacol. Ther. (2005) 22:789-794.
   PubMedGoogle Scholar
• BELLUZZI A, BRIGNOLA C, CAMPIERI M et al.: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med. (1996) 334:1557-1560.
   PubMed Web of Science ®Google Scholar
• ROMANO C, CUCCHIARA S, BARABINO A, ANNESE V, SFERLAZZAS C: Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J. Gastroenterol. (2005) 11:7118-7121.
   PubMed Web of Science ®Google Scholar
• SUMMERS RW, ELLIOTT DE, URBAN JF Jr, THOMPSON R, WEINSTOCK JV: Trichuris suis therapy in Crohn's disease. Gut (2005) 54:87-90.
   PubMed Web of Science ®Google Scholar
• KIRSCHNER BS, SUTTON MM: Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology (1986) 91:830-836.
   PubMed Web of Science ®Google Scholar
• BALLINGER AB, CAMACHO-HUBNER C, CROFT NM: Growth failure and intestinal inflammation. QJM (2001) 94:121-125.
   PubMed Web of Science ®Google Scholar
• BRAEGGER CP, TORRESANI T, MURCH SH et al.: Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (1993) 16:49-52.
   PubMed Web of Science ®Google Scholar
• CALENDA KA, SCHORNAGEL IL, SADEGHI-NEJAD A, GRAND RJ: Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm. Bowel Dis. (2005) 11:435-441.
   PubMed Web of Science ®Google Scholar
• SLONIM AE, BULONE L, DAMORE MB et al.: A preliminary study of growth hormone therapy for Crohn's disease. N. Engl. J. Med. (2000) 342:1633-1637.
   PubMed Web of Science ®Google Scholar
• SANDS BE, SANDBORN WJ, WOLF DC et al.: Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J. Clin. Gastroenterol. (2006) 40:482-489.
   PubMed Web of Science ®Google Scholar
• CUTHBERT AP, FISHER SA, MIRZA MM et al.: The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology (2002) 122:867-874.
   PubMed Web of Science ®Google Scholar
• RUSSELL RK, DRUMMOND HE, NIMMO EE et al.: Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm. Bowel Dis. (2005) 11:955-964.
   PubMed Web of Science ®Google Scholar
• LEVINE A, KARBAN A, ELIAKIM R et al.: A polymorphism in the TNF-α promoter gene is associated with pediatric onset and colonic location of Crohn's disease. Am. J. Gastroenterol. (2005) 100:407-413.
   PubMedGoogle Scholar
• RUTGEERTS P, VERMEIRE S, VAN ASSHE AG: Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut (2007) 56:453-455.
   PubMed Web of Science ®Google Scholar
• ESCHER JC: Mucosal healing in pediatric Crohn's disease: pro/con balance. Inflamm. Bowel Dis. (2004) 10:484.
   Google Scholar
• D'HAENS G: Mucosal healing in pediatric Crohn's disease: the goal of medical treatment. Inflamm. Bowel Dis. (2004) 10:479-480.
   PubMed Web of Science ®Google Scholar
• BREMNER A, ROKED S, ROBINSON R, PHILLIPS I, BEATTIE M: Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. (2005) 94:1855-1858.
   PubMed Web of Science ®Google Scholar
• COSTA F, MUMOLO MG, CECCARELLI L et al.: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut (2005) 54:364-368.
   PubMed Web of Science ®Google Scholar